SCHEMBL25900433

SCHEMBL25900433

CC(C)C1CCCN(C(=O)N(C)C(C)C)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.35
CPN1 P15169 1/20 0.35
CPB2 Q96IY4 1/20 0.35
ACKR3 P25106 1/20 0.34
PLAT P00750 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
GAA P10253 2/20 0.33
HCRTR2 O43614 3/20 0.33
RAB9A P51151 2/20 0.33
ALDH1A1 P00352 2/20 0.33
LMNA P02545 1/20 0.33
NPC1 O15118 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23337941 0.95 HTT (0.35) HPGDCPN1CPB2ACKR3PLAT
SCHEMBL23338576 0.90 MEN1 (0.36) CPN1CPB2ACKR3MEN1KMT2A
SCHEMBL23337947 0.87 MEN1 (0.41) MEN1KMT2ASMN1; SMN2GAAHCRTR2
SCHEMBL9918326 0.86 MEN1 (0.46) HPGDCPN1CPB2MEN1KMT2A
SCHEMBL9918307 0.86 MEN1 (0.46) HPGDCPN1CPB2MEN1KMT2A
SCHEMBL25900393 0.82 ACKR3 (0.33) ACKR3
SCHEMBL7883654 0.79 EPHX2 (0.40) HPGDCPN1CPB2PLATGAA
SCHEMBL22875243 0.79 MEN1 (0.41) CPN1CPB2ACKR3MEN1KMT2A
SCHEMBL463524 0.79 EPHX2 (0.40) HPGDCPN1CPB2PLATGAA
SCHEMBL12514730 0.79 CPN1 (0.42) HPGDCPN1CPB2PLATMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230374035-A1 RAS INHIBITORS Revolution Medicines, Inc. 2023-11-23 US disclosed
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-07-27 US disclosed
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS KRAS, HRAS, MTOR HPGD 3593/4885CPN1 3637/4885CPB2 3975/4885
US-20230374035-A1 RAS INHIBITORS KRAS, NRAS, HRAS HPGD 3002/4885CPN1 2910/4885CPB2 3348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.